390 related articles for article (PubMed ID: 26857646)
1. Stratification of aggressive prostate cancer from indolent disease-Prospective controlled trial utilizing expression of 11 genes in apparently benign tissue.
Alinezhad S; Väänänen RM; Tallgrén T; Perez IM; Jambor I; Aronen H; Kähkönen E; Ettala O; Syvänen K; Nees M; Kallajoki M; Taimen P; Boström PJ; Pettersson K
Urol Oncol; 2016 Jun; 34(6):255.e15-22. PubMed ID: 26857646
[TBL] [Abstract][Full Text] [Related]
2. Prostate Cancer Risk Stratification in Men With a Clinical Suspicion of Prostate Cancer Using a Unique Biparametric MRI and Expression of 11 Genes in Apparently Benign Tissue: Evaluation Using Machine-Learning Techniques.
Montoya Perez I; Jambor I; Pahikkala T; Airola A; Merisaari H; Saunavaara J; Alinezhad S; Väänänen RM; Tallgrén T; Verho J; Kiviniemi A; Ettala O; Knaapila J; Syvänen KT; Kallajoki M; Vainio P; Aronen HJ; Pettersson K; Boström PJ; Taimen P
J Magn Reson Imaging; 2020 May; 51(5):1540-1553. PubMed ID: 31588660
[TBL] [Abstract][Full Text] [Related]
3. Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment.
Tomlins SA; Day JR; Lonigro RJ; Hovelson DH; Siddiqui J; Kunju LP; Dunn RL; Meyer S; Hodge P; Groskopf J; Wei JT; Chinnaiyan AM
Eur Urol; 2016 Jul; 70(1):45-53. PubMed ID: 25985884
[TBL] [Abstract][Full Text] [Related]
4. Urine TMPRSS2:ERG fusion transcript integrated with PCA3 score, genotyping, and biological features are correlated to the results of prostatic biopsies in men at risk of prostate cancer.
Cornu JN; Cancel-Tassin G; Egrot C; Gaffory C; Haab F; Cussenot O
Prostate; 2013 Feb; 73(3):242-9. PubMed ID: 22821767
[TBL] [Abstract][Full Text] [Related]
5. Comparative assessment of urinary prostate cancer antigen 3 and TMPRSS2:ERG gene fusion with the serum [-2]proprostate-specific antigen-based prostate health index for detection of prostate cancer.
Stephan C; Jung K; Semjonow A; Schulze-Forster K; Cammann H; Hu X; Meyer HA; Bögemann M; Miller K; Friedersdorff F
Clin Chem; 2013 Jan; 59(1):280-8. PubMed ID: 23213079
[TBL] [Abstract][Full Text] [Related]
6. Prospective multicentre evaluation of PCA3 and TMPRSS2-ERG gene fusions as diagnostic and prognostic urinary biomarkers for prostate cancer.
Leyten GH; Hessels D; Jannink SA; Smit FP; de Jong H; Cornel EB; de Reijke TM; Vergunst H; Kil P; Knipscheer BC; van Oort IM; Mulders PF; Hulsbergen-van de Kaa CA; Schalken JA
Eur Urol; 2014 Mar; 65(3):534-42. PubMed ID: 23201468
[TBL] [Abstract][Full Text] [Related]
7. Rational basis for the combination of PCA3 and TMPRSS2:ERG gene fusion for prostate cancer diagnosis.
Robert G; Jannink S; Smit F; Aalders T; Hessels D; Cremers R; Mulders PF; Schalken JA
Prostate; 2013 Jan; 73(2):113-20. PubMed ID: 22674214
[TBL] [Abstract][Full Text] [Related]
8. Prognostic Significance of TMPRSS2-ERG Fusion Gene in Prostate Cancer.
Kulda V; Topolcan O; Kucera R; Kripnerova M; Srbecka K; Hora M; Hes O; Klecka J; Babuska V; Rousarova M; Benson V; Pesta M
Anticancer Res; 2016 Sep; 36(9):4787-93. PubMed ID: 27630329
[TBL] [Abstract][Full Text] [Related]
9. Combining urinary detection of TMPRSS2:ERG and PCA3 with serum PSA to predict diagnosis of prostate cancer.
Salami SS; Schmidt F; Laxman B; Regan MM; Rickman DS; Scherr D; Bueti G; Siddiqui J; Tomlins SA; Wei JT; Chinnaiyan AM; Rubin MA; Sanda MG
Urol Oncol; 2013 Jul; 31(5):566-71. PubMed ID: 21600800
[TBL] [Abstract][Full Text] [Related]
10. The performance and limitations of PCA3, TMPRSS2:ERG, HOXC6 and DLX1 urinary markers combined in the improvement of prostate cancer diagnostics.
Mytsyk Y; Nakonechnyi Y; Dosenko V; Kowal P; Pietrus M; Gazdikova K; Labudova M; Caprnda M; Prosecky R; Dragasek J; Kruzliak P; Dats R
Clin Biochem; 2023 Jun; 116():120-127. PubMed ID: 37121562
[TBL] [Abstract][Full Text] [Related]
11. Urine TMPRSS2: ERG Fusion Transcript as a Biomarker for Prostate Cancer: Literature Review.
Sanguedolce F; Cormio A; Brunelli M; D'Amuri A; Carrieri G; Bufo P; Cormio L
Clin Genitourin Cancer; 2016 Apr; 14(2):117-21. PubMed ID: 26774207
[TBL] [Abstract][Full Text] [Related]
12. [PCA3 AND TMPRSS2:ERG GENES EXPRESSION IN BIOPSIES OF BENIGN PROSTATE HYPERPLASIA, INTRAEPITHELIAL NEOPLASIA, AND PROSTATE CANCER].
Mikhaylenko DS; Perepechin DV; Grigoryeva MV; Zhinzhilo TA; Safronova NY; Efremov GD; Sivkov AV
Urologiia; 2015; (5):46-50. PubMed ID: 26859937
[TBL] [Abstract][Full Text] [Related]
13. IMPROD biparametric MRI in men with a clinical suspicion of prostate cancer (IMPROD Trial): Sensitivity for prostate cancer detection in correlation with whole-mount prostatectomy sections and implications for focal therapy.
Merisaari H; Jambor I; Ettala O; Boström PJ; Montoya Perez I; Verho J; Kiviniemi A; Syvänen K; Kähkönen E; Eklund L; Pahikkala T; Vainio P; Saunavaara J; Aronen HJ; Taimen P
J Magn Reson Imaging; 2019 Nov; 50(5):1641-1650. PubMed ID: 30903647
[TBL] [Abstract][Full Text] [Related]
14. A molecular signature of PCA3 and ERG exosomal RNA from non-DRE urine is predictive of initial prostate biopsy result.
Donovan MJ; Noerholm M; Bentink S; Belzer S; Skog J; O'Neill V; Cochran JS; Brown GA
Prostate Cancer Prostatic Dis; 2015 Dec; 18(4):370-5. PubMed ID: 26345389
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of urinary prostate cancer antigen-3 (PCA3) and TMPRSS2-ERG score changes when starting androgen-deprivation therapy with triptorelin 6-month formulation in patients with locally advanced and metastatic prostate cancer.
Martínez-Piñeiro L; Schalken JA; Cabri P; Maisonobe P; de la Taille A;
BJU Int; 2014 Oct; 114(4):608-16. PubMed ID: 24806330
[TBL] [Abstract][Full Text] [Related]
16. Detection of TMPRSS2-ERG Fusion Transcript in Biopsy Specimen of Prostate Cancer Patients: A Single Centre Experience.
Trifunovski A; Dimovski A; Dohcev S; Stavridis S; Stankov O; Saidi S; Gjorgjievska M; Popov Z
Pril (Makedon Akad Nauk Umet Odd Med Nauki); 2020 Jun; 41(1):5-14. PubMed ID: 32573479
[TBL] [Abstract][Full Text] [Related]
17. Novel biparametric MRI and targeted biopsy improves risk stratification in men with a clinical suspicion of prostate cancer (IMPROD Trial).
Jambor I; Boström PJ; Taimen P; Syvänen K; Kähkönen E; Kallajoki M; Perez IM; Kauko T; Matomäki J; Ettala O; Merisaari H; Kiviniemi A; Dean PB; Aronen HJ
J Magn Reson Imaging; 2017 Oct; 46(4):1089-1095. PubMed ID: 28165653
[TBL] [Abstract][Full Text] [Related]
18. Assessment of long-term outcomes associated with urinary prostate cancer antigen 3 and TMPRSS2:ERG gene fusion at repeat biopsy.
Merdan S; Tomlins SA; Barnett CL; Morgan TM; Montie JE; Wei JT; Denton BT
Cancer; 2015 Nov; 121(22):4071-9. PubMed ID: 26280815
[TBL] [Abstract][Full Text] [Related]
19. Detection of High-grade Prostate Cancer Using a Urinary Molecular Biomarker-Based Risk Score.
Van Neste L; Hendriks RJ; Dijkstra S; Trooskens G; Cornel EB; Jannink SA; de Jong H; Hessels D; Smit FP; Melchers WJ; Leyten GH; de Reijke TM; Vergunst H; Kil P; Knipscheer BC; Hulsbergen-van de Kaa CA; Mulders PF; van Oort IM; Van Criekinge W; Schalken JA
Eur Urol; 2016 Nov; 70(5):740-748. PubMed ID: 27108162
[TBL] [Abstract][Full Text] [Related]
20. Urine TMPRSS2:ERG fusion transcript stratifies prostate cancer risk in men with elevated serum PSA.
Tomlins SA; Aubin SM; Siddiqui J; Lonigro RJ; Sefton-Miller L; Miick S; Williamsen S; Hodge P; Meinke J; Blase A; Penabella Y; Day JR; Varambally R; Han B; Wood D; Wang L; Sanda MG; Rubin MA; Rhodes DR; Hollenbeck B; Sakamoto K; Silberstein JL; Fradet Y; Amberson JB; Meyers S; Palanisamy N; Rittenhouse H; Wei JT; Groskopf J; Chinnaiyan AM
Sci Transl Med; 2011 Aug; 3(94):94ra72. PubMed ID: 21813756
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]